Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04986579 · ClinicalTrials.gov registry record · Phase 2
Scalp Cooling in MBC
A Phase 2 study of Metastatic Breast Cancer and Chemotherapy-induced Alopecia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT04986579 is a Phase 2 study of Metastatic Breast Cancer and Chemotherapy-induced Alopecia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 120 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (41% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04986579, a Phase 2 study of Metastatic Breast Cancer and Chemotherapy-induced Alopecia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study intervention involved in this study is: * Paxman Scalp Cooling System
Conditions Studied
Interventions
- DRUG Sacituzumab govitecan
- DRUG Eribulin
- DRUG Trastuzumab deruxtecan
- DEVICE Paxman Scalp Cooling System
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04986579
The ClinicalTrials.gov registry entry for NCT04986579 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (41% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Sacituzumab govitecan is the first listed.
NCT04986579 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04986579 about?
NCT04986579 is a clinical study titled "Scalp Cooling in MBC". This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin. The name of the study interve...
What is the current status of trial NCT04986579?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2021-10-07. Estimated completion is 2028-06-01.
What conditions does trial NCT04986579 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Chemotherapy-induced Alopecia.
What interventions are being tested in trial NCT04986579?
The interventions under investigation include: Sacituzumab govitecan (DRUG), Eribulin (DRUG), Trastuzumab deruxtecan (DRUG), Paxman Scalp Cooling System (DEVICE).
Who is sponsoring clinical trial NCT04986579?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04986579 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Breast Cancer
All registered trials for this condition
Chemotherapy-induced Alopecia
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.